Literature DB >> 28845144

The Microbiome and the Liver.

Bernd Schnabl1.   

Abstract

Year:  2014        PMID： 28845144      PMCID： PMC5566188     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis.

Authors:  Georgios N Kalambokis; Epameinondas V Tsianos
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

Review 2.  Interactions between the intestinal microbiome and liver diseases.

Authors:  Bernd Schnabl; David A Brenner
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

Review 3.  Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.

Authors:  Ekihiro Seki; Bernd Schnabl
Journal:  J Physiol       Date:  2011-11-28       Impact factor: 5.182

4.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.

Authors:  J S Bajaj; D M Heuman; P B Hylemon; A J Sanyal; P Puri; R K Sterling; V Luketic; R T Stravitz; M S Siddiqui; M Fuchs; L R Thacker; J B Wade; K Daita; S Sistrun; M B White; N A Noble; C Thorpe; G Kakiyama; W M Pandak; M Sikaroodi; P M Gillevet
Journal:  Aliment Pharmacol Ther       Date:  2014-03-16       Impact factor: 8.171

Review 5.  Host-microbiome interactions in alcoholic liver disease.

Authors:  Peng Chen; Bernd Schnabl
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519
  5 in total
  1 in total

Review 1.  Antimicrobial proteins: intestinal guards to protect against liver disease.

Authors:  Tim Hendrikx; Bernd Schnabl
Journal:  J Gastroenterol       Date:  2018-11-03       Impact factor: 7.527
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.